YOLFTbeta
IBKS No2 SPAC

IBKS No2 SPAC

204840 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

3,365.00KRW+5.00 (+0.15%)

Price History

Full chart

Market Stats

Previous Close3,360.00
Open3,365.00
Day Range3,280.00 – 3,485.00
52-Week Range3,760.00 – 6,650.00
Volume9.41K
Market Cap65.76B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.44
50-Day Avg4,425.80
200-Day Avg4,872.73

About

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further, it provides Cabalin CR extended-release tablet and Jample Ibufen syrup for the nervous system and sensory organs; Gisoren tablets for individual organs, digestive system, and peptic ulcer drugs; and Genstring Troki for treating individual organs and digestive system, as well as oral use. GL Pharm Tech Corp. was founded in 2002 and is headquartered in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yong-Il Kim
  • Employees33
  • HeadquartersRoom 210, Building B, Seongnam-si, South Korea, Korea
  • Websitehttps://www.glpt.co.kr

Leadership

  • Mr. Yong-Il KimCEO, CTO & Executive Director · b. 1979
  • Mr. SungPil JinCEO & Executive Director · b. 1969
  • Mr. YoungPil KimMD & CFO · b. 1979
  • Mr. JinHyo JoSenior MD & Head of Development Headquarters · b. 1980
  • Mr. JeongMin ChoiMD & CCO · b. 1976

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.47B4.64B2.41B8.00B10.61B11.99B12.43B16.73B26.03B26.05B35.27B
Growth (%)--28.40%-47.93%+231.34%+32.63%+13.01%+3.65%+34.63%+55.62%+0.06%+35.40%
Cost of Revenue3.50B4.74B3.68B7.21B8.58B8.68B8.66B11.85B17.32B15.74B20.94B
Gross Profit2.97B-100.92M-1.27B783.61M2.03B3.31B3.77B4.88B8.71B10.31B14.33B
Gross Margin45.89%-2.18%-52.44%9.80%19.12%27.62%30.33%29.15%33.46%39.57%40.63%
Operating Expense3.04B2.66B3.02B5.33B7.30B6.12B6.74B7.12B11.43B12.07B14.06B
Operating Income-71.77M-2.76B-4.28B-4.55B-5.27B-2.81B-2.97B-2.24B-2.72B-1.77B268.48M
Operating Margin-1.11%-59.64%-177.51%-56.88%-49.67%-23.46%-23.92%-13.41%-10.43%-6.79%0.76%
EBITDA-------1.74B-1.02B147.61M1.67B
EBITDA Margin-------10.39%-3.93%0.57%4.73%
Net Income16.82M-5.49B-4.24B-5.35B-5.52B-3.36B-3.73B-790.17M-3.75B-2.34B12.49M
Net Income Margin0.26%-118.53%-175.52%-66.88%-51.99%-28.00%-30.00%-4.72%-14.40%-8.97%0.04%
R&D1.03B1.13B1.46B1.68B-2.52B2.97B1.97B2.38B2.33B1.92B
R&D as % of Total Revenue15.97%24.38%60.44%21.00%-21.00%23.94%11.76%9.13%8.93%5.43%
Interest Expense00000827.49M866.88M425.42M782.88M769.42M589.67M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%6.90%6.98%2.54%3.01%2.95%1.67%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.86B12.35B15.02B31.56B26.55B34.94B31.89B40.85B39.87B42.44B48.81B
Total Liabilities5.68B3.78B9.09B23.74B24.19B20.63B15.05B24.76B27.59B22.77B28.90B
Total Equity2.70B8.57B5.94B7.82B2.36B14.31B16.85B16.09B12.28B19.67B19.92B
Cash750.67M584.36M362.01M1.73B324.13M9.49B6.19B4.64B4.14B4.26B3.04B
Total Debt-132.15M7.13B14.21B5.55B10.28B-----
Net Debt-----3.34B1.49B9.14B13.49B10.07B15.39B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.40B-3.99B-3.82B-3.80B-1.07B-2.67B-2.27B-1.27B-3.76B-4.65B-1.12B
Investing Cash Flow-4.06B5.47B-3.01B698.24M-15.93M808.52M-1.90B-5.43B-570.14M-1.58B-
Financing Cash Flow2.17B-1.64B6.61B4.47B-320.03M11.02B867.67M6.07B3.83B6.35B-
Capital Expenditure442.53M482.27M676.35M2.40B989.10M1.10B1.33B6.44B579.32M391.81M4.42B
Free Cash Flow------3.76B-3.61B-7.71B-4.34B-5.04B-5.55B
FCF to OCF-----141.20%158.83%607.96%115.41%108.43%493.41%

Earnings

Report DateMar 31, 2015Jun 30, 2015Sep 30, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Feb 28, 2024Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------
EPS Actual7.5510.713.4610.823.87-644.55-89.45-252.62-186.27-161.47-50.99-255.9637.31-458.11-161.63-151.57-139.22-78.07-75.00-83.97-149.38-45.63-135.78-35.44-209.21107.07-24.6630.03-48.16-95.53-77.27-15.83-122.45-44.37-7.586.071.563.718.42-12.99-7.745.26
Surprise------------------------------------------
Timing-------------------------------After-hours----------

Key Statistics & Ratios

Market Cap65.76B
Enterprise Value84.42B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.72
Price / Book3.37
Revenue (TTM)38.21B
Gross Profit (TTM)15.33B
EBITDA1.36B
Profit Margin-0.28%
Operating Margin2.38%
Return on Equity-0.54%
Return on Assets0.30%
Shares Outstanding15.51M
Shares Float14.59M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 11, 20261:5
  • Dec 5, 20191807:1700